Skip to content

A human study to evaluate safety and effectiveness of Phellinus baumii extract complex on platelet aggregation response and blood flow: a randomized, double-blind, parallel, placebo-controlled study

A human study to evaluate safety and effectiveness of Phellinus baumii extract complex on platelet aggregation response and blood flow: a randomized, double-blind, parallel, placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0001642
Enrollment
72
Registered
2015-10-01
Start date
2015-10-02
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects were randomly allocated at placebo group, Phellinus baumii low group or Phellinus baumii high group. Then consumption once a day during 4 weeks.

Sponsors

Ewha Womans University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects who informed consent Age 20-70 years Smoker (smoking = 1 year and = 10 cigarettes)

Exclusion criteria

Exclusion criteria: BMI = 18.5kg/m2 or BMI = 35kg/m2 Body weight fluctuation of 10% or more in the past 8weeks Excessive activity Takes hormone therapy (female) Drinking alcohol more than 140g/week Platelet function disorder Taking anti-platelet medication (aspirin, antiplatelet agent, non-steroidal anti-inflammatory drugs) Cardiovascular or haematological disorders, insulin resistance, diagnosed non-insulin dependent diabetes disease (Cardiovascular disease, heart failure, myocardial infarction, cerebrovascular disease, arteriosclerosis, diabetes, thyroid abnormality, ulcer, gastric bleeding, infectious diseases, systemic inflammatory diseases, acute inflammation, malignancy, renal disease, renal function, liver disease, lung disease, blood coagulopathy) Take oriental medicine or other medicine and functional foods continuously in the 4 weeks Subjects who have hypersensitivity about test material Participate other human study in the 12 weeks Pregnat woman or lactating woman Subjects who unsuiable about this study

Design outcomes

Primary

MeasureTime frame
Platelet aggregation test

Secondary

MeasureTime frame
Blood flow

Countries

Korea, Republic of

Contacts

Public ContactYeni Lim

Ewha Womans University

yeni0223@hanmail.net+82-2-3277-4228

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026